Peng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peng Zhao has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Linghang Zhuang
Eternity Bioscience Inc., 6 Cedarbrook Drive, Cranbury, New Jersey 08512, United States
3 shared publicationsSuxing Liu
Eternity Bioscience Inc., 6 Cedarbrook Drive, Cranbury, New Jersey 08512, United States
3 shared publicationsWeikang Tao
Shanghai Hengrui Pharmaceutical Co. Ltd., 279 Wenjing Road, Shanghai 200245, China
3 shared publicationsYuna Yan
Shanghai Hengrui Pharmaceutical Co. Ltd., 279 Wenjing Road, Shanghai 200245, China
3 shared publicationsChang Bai
Shanghai Hengrui Pharmaceutical Co. Ltd., 279 Wenjing Road, Shanghai 200245, China
2 shared publicationsFan Zhang
Eternity Bioscience Inc., 6 Cedarbrook Drive, Cranbury, NJ 08512, USA
2 shared publications
Latest Publications
- 22 June 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (7) , 458-467
Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis
Osteoarthritis (OA) treatment is a highly unmet medical need. Development of a disease-modifying OA drug (DMOAD) is challenging with no approved drugs on the market. Inhibition of ADATMS-4/5 is a promising OA therapeutics to target cartilage degradation and potentially can reduce joint pain and restore its normal function. Starting from the reported ADAMTS-5 inhibitor GLPG1972, we applied a scaffold hopping strategy to generate a novel isoindoline amide scaffold. Representative compound 18 showed high potency in ADATMS-4/5 inhibition, as well as good selectivity over a panel of other metalloproteases. In addition, compound 18 exhibited excellent druglike properties and showed better pharmacokinetic (PK) profiles than GLPG1972 cross-species. Compound 18 demonstrated dose-dependent efficacy in two in vivo rat osteoarthritis models.
- 22 June 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 5 (7) , 458-467
Discovery of Isoindoline Amide Derivatives as Potent and Orally Bioavailable ADAMTS-4/5 Inhibitors for the Treatment of Osteoarthritis
Osteoarthritis (OA) treatment is a highly unmet medical need. Development of a disease-modifying OA drug (DMOAD) is challenging with no approved drugs on the market. Inhibition of ADATMS-4/5 is a promising OA therapeutics to target cartilage degradation and potentially can reduce joint pain and restore its normal function. Starting from the reported ADAMTS-5 inhibitor GLPG1972, we applied a scaffold hopping strategy to generate a novel isoindoline amide scaffold. Representative compound 18 showed high potency in ADATMS-4/5 inhibition, as well as good selectivity over a panel of other metalloproteases. In addition, compound 18 exhibited excellent druglike properties and showed better pharmacokinetic (PK) profiles than GLPG1972 cross-species. Compound 18 demonstrated dose-dependent efficacy in two in vivo rat osteoarthritis models.
- 8 March 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 63, 128666
Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer
- 8 March 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 63, 128666
Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 228, 114040
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers
- 1 January 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 228, 114040
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers